NeoGenomics (NEO)
NASDAQ:NEO
Want to see NEO full AI Analyst Report?
Earnings Data
Report Date
Aug 04, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.03Last Year’s EPS
0.03Same Quarter Last Year
Moderate Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive operational and financial trajectory: consistent double-digit top-line growth, strong NGS performance (+26% YoY) with favorable mix shift (NGS now ~1/3 of clinical revenue), adjusted EBITDA expansion (+27% YoY), early commercial and reimbursement wins (PanTracer MolDX approval, RaDaR ST launch), and an increase to full-year revenue guidance. Offsetting risks include a meaningful nonclinical decline (-15% YoY), first-quarter gross margin headwinds (–80 bps) from acquisition and pre-approval launch timing, freight/fuel cost pressure, payer coverage timing for new products, and the need to refinance a sizable convertible in 2028. On balance, the positive growth, margin recovery plans, product launches, and improved cash flow prospects outweigh the near-term headwinds.Company Guidance
Top-line Revenue Growth
Total Q1 revenue of $186.7M, up 11% year-over-year, exceeding guidance; clinical revenue $171.2M, up 14% year-over-year.
Strong NGS Performance and Mix Shift
NGS revenue grew 26% year-over-year, driven by 16% volume growth and higher AUP; NGS now represents ~1/3 of clinical revenue and is scaling 3–4x faster than core clinical business.
Improved Profitability Metrics
Adjusted EBITDA of $9M, up 27% year-over-year; adjusted EBITDA margin expanded ~60 basis points year-over-year.
AUP and Volume Momentum
Average unit price (AUP) increased 8% year-over-year and volumes grew 6% year-over-year; same-store revenue $167.9M, up 12% driven by +3% volumes and +9% AUP.
Product and Reimbursement Catalysts
Full clinical launch of RaDaR ST (detection down to 1 ppm) and MolDX reimbursement for PanTracer Liquid (approval in March), with PanTracer LBx expected to contribute mid-single-digit millions in revenue.
Early Adoption Signals for RaDaR ST
~29% of prior RaDaR 1.0 customers have ordered RaDaR ST since launch; 34% of RaDaR ST orders included additional NEO tests; all results delivered faster than published turnaround times.
Raised 2026 Revenue Guidance
Full-year 2026 revenue guidance increased to $797M–$803M (from $793M–$801M); quarterly cadence guidance tightened to ~9% YoY growth in Q2, 9–10% in Q3 and >10% in Q4.
Cash Flow and Liquidity Improvement
Cash used in operations improved to $8.1M in Q1 (from ~$25.3M YoY); ending cash balance $146M and management expects free cash flow positive for the year.
Commercial and Operational Investments
Plan to add ~25 sales resources by Q3 to support RaDaR ST and PanTracer adoption; Pathline acquisition strengthened Northeast presence (growing at 1.5x national average); ~330 interfaces developed including Epic Aura to drive adoption.
Pipeline and R&D Progress
Targeted R&D investments in whole genome sequencing and next-generation MRD platform (data generation expected next year, potential launch as early as 2028); expansion of nonclinical offerings (AML flow panel, IHC markers).
NEO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NEO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 28, 2026 | $9.02 | $8.96 | -0.67% |
Feb 17, 2026 | $11.38 | $11.44 | +0.53% |
Oct 28, 2025 | $10.16 | $9.92 | -2.36% |
Jul 29, 2025 | $6.46 | $5.25 | -18.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does NeoGenomics (NEO) report earnings?
NeoGenomics (NEO) is schdueled to report earning on Aug 04, 2026, TBA (Confirmed).
What is NeoGenomics (NEO) earnings time?
NeoGenomics (NEO) earnings time is at Aug 04, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NEO EPS forecast?
NEO EPS forecast for the fiscal quarter 2026 (Q2) is 0.03.
